更多栏目
搜索
China Regulations Tracker: Mar 2021
储旻华·2021-05-14
PharmaDJ
Leaders Endorse Volume-Based Procurement at China's Annual "Two Sessions"

China Regulations Tracker: Mar 2021


Writer: Minhua Chu

Editor: Justin Fischer


China's annual 'Two Sessions', or Lianghui — the National People’s Congress (NPC) and the Chinese People’s Political Consultative Conference (CPPCC), convened in March to set the national socio-economic  and political priorities for for 2021.


Premier Li Keqiang delivered the annual government work report. In it, he mentioned that more drugs for chronic and common diseases and high-value medical consumables would be made eligible for volume-based procurement (VBP). Under a VBP system, state authorities make bids to purchase a guaranteed volume of drugs from manufacturers. The intended effect is to make drugs more affordable.


VBP was often mentioned during this year's 'Two Sessions'. When addressing the CPPCC, President Xi Jinping noted the importance of continuing medical reimbursement reforms, regularly carrying out VBP, and improving its institutions.


Below are some other highlights relevant to the biopharmaceutical industry that were laid out in the annual government work report:


· Promoting the development of COVID-19 vaccines and administering them for free; increasing nucleic acid testing capacity; providing free treatment for COVID-19 patients.

· Deeper public hospital reform, setting up the hierarchical medical service system.

· Promoting the development of Traditional Chinese Medicine (TCM) and informatization medical institutions.

· Promoting coordination in government-led basic medical insurance at the provincial level; gradually allowing outpatient expenses to be covered in medical insurance social pooling funds.

· Increasing the supply and stabilizing the price of scarce drugs.


Additionally, the new Regulation on the Supervision and Administration of Medical Devices was published in March. Enforcement begins on June 1 of this year. Since the last regulation was formulated in 2000, it was revised comprehensively in 2014, followed by amendments in 2017. 




文章关键字: the National People’s Congress (NPC) volume-based procurement (VBP) COVID-19 vaccines Traditional Chinese Medicine (TCM) the new Regulation on the Supervision and Administration of Medical Devices
3166
谁阅读了此文章?
回复评论0
登录后回复评论,不超过1024个字(当前剩余字数:1024)
储旻华 个人用户

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

联系方式

联系电话

电子邮箱

chu.minhua@pharmadj.com

公司名称

研发客

公司网站

公司地址

进入主页
Copyright © 2016-2021 研发客.All Rights Reserved.   建议反馈: Support@PharmaDJ.com   备案/许可证编号:沪ICP备17054709号-1   联系电话:021 - 88194359
关于研发客 | 加入会员 | 联系我们| 知识产权声明